Europe Ophthalmology Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2023 –2030 |
 Marktgröße (Basisjahr) | USD 14,789.41 Million |
 Marktgröße (Prognosejahr) | USD 23,186.51 Million |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Europäischer Markt für Augenheilkunde nach Produkt (Geräte, Medikamente und andere), Krankheiten (Glaukom, Katarakt, altersbedingte Makuladegeneration, entzündliche Erkrankungen, Refraktionsstörungen und andere), Verschreibungsmodus (Generika und Marken), Medikamententyp (verschreibungspflichtig und rezeptfrei), Verabreichungsweg (oral, topisch, injizierbar, lokal am Auge und andere), Endbenutzer (Krankenhäuser, Kliniken, häusliche Pflege und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere) – Branchentrends und Prognose bis 2030.
Europa: Marktanalyse und Größe der Augenheilkunde
Einer der Hauptfaktoren, die das Wachstum des Augenheilkundemarktes vorantreiben, ist die zunehmende Verbreitung von Augenerkrankungen und Augenschmerzen. Die fortlaufenden klinischen Studien, die von mehreren Pharmaunternehmen durchgeführt werden, um Behandlungsmöglichkeiten zu verbessern, und die Belastung durch bestimmte Toxine oder Umweltveränderungen erhöhen die Anzahl augenheilkundlicher Produkte und führen zu einer Marktexpansion. Der Markt wird auch durch einen zunehmend unhygienischen und sitzenden Lebensstil sowie einen Anstieg traumatischer Verletzungen beeinflusst. Die hohen Kosten und Risiken im Zusammenhang mit Augenoperationen und -behandlungen, der Mangel an Krankenversicherung in der Bevölkerung, insbesondere in Entwicklungsländern, und die lange Zeitspanne für die Herstellung und Formulierung augenheilkundlicher Medikamente wirken sich jedoch im Prognosezeitraum als hemmende Faktoren für den europäischen Augenheilkundemarkt aus.
Der europäische Markt für Augenheilkunde dürfte im Prognosezeitraum von 2023 bis 2030 ein Marktwachstum verzeichnen. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum von 2023 bis 2030 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 5,8 % wächst und von 14.789,41 Millionen USD im Jahr 2022 auf 23.186,51 Millionen USD im Jahr 2030 ansteigen dürfte.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2023 bis 2030 |
|
Basisjahr |
2022 |
|
Historische Jahre |
2021 (anpassbar auf 2015–2020) |
|
Quantitative Einheiten |
Umsatz in Mio. USD |
|
Abgedeckte Segmente |
Nach Produkttyp (Gerät, Medikamente und andere), Krankheiten ( Glaukom , Katarakt, altersbedingte Makuladegeneration, entzündliche Erkrankungen, Refraktionsstörungen und andere), Verschreibungsmodus (Generika und Markenprodukte), Medikamententyp (verschreibungspflichtig und rezeptfrei (OTC)), Verabreichungsweg (oral, topisch, injizierbar, lokal okular und andere), Endbenutzer (Krankenhäuser, Kliniken, häusliche Pflege und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere) |
|
Abgedeckte Länder |
Russland, Spanien, Türkei, Deutschland, Italien, Großbritannien, Frankreich, Ungarn, Österreich, Schweiz, Niederlande, Polen, Irland, Norwegen, Litauen, Restliches Europa |
|
Abgedeckte Marktteilnehmer |
Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Reichert, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Lumenis Be Ltd., Pfizer Inc. und Ziemer Ophthalmic Systems AG, unter anderem. |
Marktdefinition
Die Augenheilkunde ist ein Zweig der Medizin, der sich mit der Anatomie, Physiologie, Behandlung und Chirurgie der Sehbahnen des Auges, einschließlich der umgebenden Bereiche und der visuellen Aspekte des Gehirns, befasst. Ophthalmische Geräte sind medizinische Geräte, die für Operationen, Diagnosen und Sehkorrekturen entwickelt wurden. Die Geräte gewannen aufgrund der hohen Prävalenz verschiedener Augenkrankheiten wie Glaukom, Katarakt und anderer Sehprobleme an Bedeutung und Einsatz. Ophthalmische Medikamente sind Medikamente, die speziell für die Behandlung verschiedener Augenkrankheiten entwickelt und verabreicht werden, darunter Farbenblindheit, diabetisches Makulaödem , Cytomegalovirus (CMV) und altersbedingte Makuladegeneration (AMD).
Dynamik des Augenheilkundemarktes
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:
Treiber
- Steigende Prävalenz von Augenerkrankungen und Augenschmerzen
Augenerkrankungen sind die Hauptursache für starke Augen- und Augenhöhlenschmerzen. Augenschmerzen treten auf der Oberfläche der Augen auf und gehen mit Symptomen wie Kratzen, Brennen oder Jucken einher. Dies kann mehrere Ursachen haben, darunter Reizung durch Fremdkörper, Infektionen oder Traumata. Wimpern oder Schmutzpartikel, Rauch, Staub oder aggressive Augenkosmetika sind die häufigsten Ursachen für Augenschmerzen, Rötungen und tränende Augen.
Die Häufigkeit von Augenschmerzen nimmt aufgrund der wachsenden chemischen Industrie und Umweltverschmutzung weltweit weiter zu. Chemische Verbrennungen und Blitzverbrennungen verursachen aufgrund von Reizungen der Augenoberfläche erhebliche und schwere Augenschmerzen. Augenlidentzündungen und Blepharitis führen zu starken Augenschmerzen, da sie die Augen und Talgdrüsen in der Umgebung empfindlicher machen. Der positive Faktor besagt, dass dies der Haupttreiber für den europäischen Augenheilkundemarkt ist.
- Anstieg traumatischer Verletzungen
Traumatische Kopfverletzungen sind eine der Ursachen für Erkrankungen wie Sehnervenerkrankungen. Eine traumatische Verletzung ist eine körperliche Verletzung, die plötzlich mit einem gewissen Schweregrad auftritt. Ein Trauma kann durch eine Vielzahl äußerer Verletzungen verursacht werden. Die häufigsten Ursachen für traumatische Verletzungen sind unter anderem Verkehrsunfälle, Sportverletzungen und Gewalt, die auch zu schweren Augenerkrankungen führen können. Die Prävalenz solcher traumatischer Verletzungen ist weltweit hoch.
Solche traumatischen Verletzungen führen daher zu Sehnervenerkrankungen, die die Bevölkerung in diesen Jahren beeinträchtigen und mit der wachsenden Bevölkerung zunehmen. Daher wird erwartet, dass ein Anstieg traumatischer Verletzungen das Marktwachstum vorantreiben wird.
Gelegenheiten
-
Anstieg der Gesundheitsausgaben und des verfügbaren Einkommens
Die Gesundheitsausgaben und ihre Wachstumsrate im Laufe der Zeit werden von einer Vielzahl wirtschaftlicher und sozialer Faktoren beeinflusst, einschließlich der Finanzierungsvereinbarungen und der Organisationsstruktur des Gesundheitssystems.
Die Gesundheitsausgaben sind weltweit gestiegen, da das verfügbare Einkommen der Menschen in vielen Ländern zunimmt. Um den Bedarf der Bevölkerung zu decken, ergreifen Regierungsbehörden und Gesundheitsorganisationen zudem Initiativen zur Erhöhung der Gesundheitsausgaben.
Steigende Gesundheitsausgaben sind auch für weiteres Wirtschaftswachstum und Wachstum im Gesundheitssektor von Vorteil. Sie sind vor allem deshalb von Vorteil, weil sie die Entwicklung besserer und fortschrittlicherer medizinischer Produkte auf dem Markt erheblich beeinflussen. Daher kann der Anstieg der Gesundheitsausgaben eine große Chance für Marktwachstum darstellen.
-
Sensibilisierung für die Prävention von Augenkrankheiten
Verschiedene Organisationen wie die Weltgesundheitsorganisation (WHO) und ihre Mitgliedstaaten, UN-Agenturen, Nichtregierungsorganisationen (NGOs) und der Privatsektor haben bedeutende Fortschritte bei der Prävention von Sehbehinderungen im Kampf gegen sichtbare Krankheiten erzielt. Aus diesem Grund ist der zweite Donnerstag im Oktober der Welttag des Sehens (WSD), ein jährlich stattfindender Aktionstag, um in Europa auf Blindheit und Sehbehinderungen aufmerksam zu machen.
Daher ist zu erwarten, dass die Programme und Initiativen zur Reduzierung der Belastung durch Augenkrankheiten im Prognosezeitraum Wachstumschancen für den europäischen Ophthalmologiemarkt schaffen werden.
Einschränkungen/Herausforderungen
- Hohe Kosten und Risiken im Zusammenhang mit Augenoperationen und -behandlungen
Die Kosten der Behandlung verschiedener Erkrankungen spielen auf dem Markt eine große Rolle. Die Behandlung von Sehnervenerkrankungen ist hochentwickelt, da die Prävalenz solcher Erkrankungen zunimmt; daher ist der Bedarf an solchen Produkten schließlich gestiegen, was wiederum die Behandlungskosten erhöht, was das Marktwachstum in den kommenden Jahren behindern kann.
Es gibt verschiedene Methoden zur Behandlung der Optikusneuritis. Einige davon sind Medikamente, die Patienten einnehmen können, wie Kortikosteroide wie Methylprednisolon, Prednison, Immunglobulin , Vitamin-B12-Spritzen und verschiedene andere Operationen. Damit sind einige Risiken verbunden.
Für einen Teil der Bevölkerung im ganzen Land ist es daher aufgrund der hohen Kosten schwierig, sich solchen Behandlungen zu unterziehen. Daher wird erwartet, dass die mit der Behandlung von Augenerkrankungen verbundenen hohen Kosten das Marktwachstum bremsen werden.
- Fachkräftemangel
Die Zahl der Augenärzte ist sowohl in Schwellen- als auch in Industrieländern gering. Für Entwicklungsländer sind die Prognosen jedoch etwas höher. Die Zahl der Augenärzte wächst kumulativ, aber nicht so schnell wie die Zahl der älteren Patienten im Alter von 60 Jahren oder älter, die eine verstärkte augenärztliche Versorgung benötigen. In den meisten Ländern besteht das Problem darin, dass die demografischen Veränderungen nicht mit der beruflichen Entwicklung Schritt halten. Es ist erforderlich, Augenpflegeteams auszubilden, um der aktuellen Zahl der Augenärzte weltweit gerecht zu werden. Der weltweit gestiegene Bedarf an Augenärzten spiegelt auch einen Anstieg der Diabetesfälle wider. Diabetiker sollten ihre Augen jährlich untersuchen lassen. Die steigende Nachfrage nach Augenärzten ist direkt proportional zur wachsenden geriatrischen Bevölkerung, da die Augenpflege ein integraler Bestandteil der Gesundheitsversorgung ist. Die Lücken im Zugang zur Versorgung können durch eine Kombination von Faktoren geschlossen werden, darunter effizientere Praxisstrukturen, Prozesse und angemessener Einsatz von Technologie.
Auswirkungen von COVID-19 auf den Ophthalmologiemarkt
Die COVID-19-Pandemie hatte große Auswirkungen auf die ophthalmologische und chirurgische Industrie. Branchenverbände im Bereich der ophthalmologischen und augenmedizinischen Produkte behaupten, dass die europäische Lieferkette für Operations-, Diagnose- und Sehpflegeprodukte erheblich beschädigt wurde, was sich auf den Endverbrauch des ophthalmologischen Marktes auswirkte. Der Verkauf von Sehpflegeprodukten im ersten Quartal 2020 verzögerte sich aufgrund logistischer und Transportprobleme erheblich. Auf der Nachfrageseite wächst der Markt, da Menschen nach dem Lockdown operiert werden müssen. Die Situation muss berücksichtigt werden und es müssen Notoperationen durchgeführt werden. Darüber hinaus ist das Marktwachstum auf der Angebotsseite negativ. Dies ist auf die Lockdown-Situationen in vielen Ländern zurückzuführen, in denen Diagnose-, Operations- und Sehpflegeinstrumente hergestellt werden.
Jüngste Entwicklungen
- Im Oktober 2022 gab Regeneron Pharmaceuticals, Inc. bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den ergänzenden Biologics License Application (sBLA) für die Injektion von EYLEA (Aflibercept) zur Behandlung der Frühgeborenenretinopathie (ROP) bei Frühgeborenen zur vorrangigen Prüfung angenommen hat. Diese Entwicklung hilft dem Unternehmen unter anderem dabei, sein Markenimage auf dem Markt für Augenheilkunde zu entwickeln.
- Im Mai 2022 hat Reichert, Inc. seine neu gestaltete Website für Refraktometer und Analyseinstrumente mit einer deutlich verbesserten Benutzererfahrung gestartet
Europa Ophthalmologie Marktumfang
Der europäische Markt für Augenheilkunde ist segmentiert in Produkte, Krankheiten, Verschreibungsarten, Arzneimitteltypen, Verabreichungswege, Endverbraucher und Vertriebskanäle. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse schwacher Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, um strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.
Produkte
- Gerät
- Medikamente
- Sonstiges
Auf der Grundlage der Produkte ist der Markt für Augenheilkunde in Geräte, Medikamente und Sonstiges segmentiert.
Krankheiten
- Glaukom
- Katarakt
- Altersbedingte Makuladegeneration
- Entzündliche Erkrankungen
- Refraktive Störungen
- Sonstiges
Auf der Grundlage von Krankheiten wird der Markt für Augenheilkunde in Glaukom, Katarakt, altersbedingte Makuladegeneration, entzündliche Erkrankungen, Refraktionsstörungen und andere unterteilt.
Rezeptmodus
- Generisch
- Gebrandmarkt
Auf Grundlage der Verschreibungsart wird der Markt für Augenheilkunde in Generika und Markenprodukte segmentiert.
Arzneimitteltyp
- Rezept
- Over the Counter (OTC)
Auf der Grundlage der Arzneimittelart ist der Markt für Augenheilkunde in verschreibungspflichtige und rezeptfreie Arzneimittel (OTC) segmentiert.
Verabreichungsweg
- Oral
- Aktuell
- Injektionen
- Lokales Okular
- Sonstiges
Auf der Grundlage der Verabreichungsart ist der Markt für Augenheilkunde in orale, topische, injizierbare, lokale okulare und andere Mittel unterteilt.
Endbenutzer
- Krankenhäuser
- Kliniken
- Häusliche Gesundheitspflege
- Sonstiges
Auf der Grundlage des Endbenutzers ist der Markt für Augenheilkunde in Krankenhäuser, Kliniken, häusliche Pflege und andere unterteilt.
Vertriebskanal
- Direkte Ausschreibung
- Einzelhandelsumsätze
- Sonstiges
Auf der Grundlage der Vertriebskanäle wird der Markt für Augenheilkunde in Direktausschreibungen, Einzelhandelsverkäufe und Sonstige segmentiert.
Regionale Analyse/Einblicke zum Augenheilkundemarkt
Der europäische Markt für Augenheilkunde ist nach Produkten, Krankheiten, Verschreibungsarten, Arzneimitteltypen, Verabreichungswegen, Endverbrauchern und Vertriebskanälen segmentiert.
Die Länder auf dem europäischen Dichtungsmarkt sind Deutschland, Italien, Großbritannien, Frankreich, Ungarn, Österreich, die Schweiz, die Niederlande, Polen, Irland, Norwegen, Litauen und das übrige Europa.
Aufgrund der Nachfrage nach ophthalmologischen Produkten dominiert Russland, und es wird erwartet, dass auch eine Steigerung der Forschungs- und Entwicklungsaktivitäten in der Branche dem Markt im Prognosezeitraum Auftrieb verleihen wird.
Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunktanalysen der nachgelagerten und vorgelagerten Wertschöpfungsketten, technische Trends, Porters Fünf-Kräfte-Analyse und Fallstudien sind einige der Hinweise, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung von Prognoseanalysen der Länderdaten werden auch die Präsenz und Verfügbarkeit europäischer Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken, die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.
Wettbewerbsumfeld und Analyse der Marktanteile im Bereich Augenheilkunde in Europa
Die Wettbewerbslandschaft des Augenheilkundemarktes liefert Einzelheiten zu den Wettbewerbern. Zu den enthaltenen Einzelheiten gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz in Europa, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den europäischen Augenheilkundemarkt.
Zu den wichtigsten Akteuren auf diesem Markt zählen unter anderem Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Reichert, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Lumenis Be Ltd., Pfizer Inc. und Ziemer Ophthalmic Systems AG.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE OPHTHALMOLOGY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE OPHTHALMOLOGY MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 STRATEGIC INITIATIVES
7 EUROPE OPHTHALMOLOGY MARKET, REGULATION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF OPHTHALMIC DISORDERS & OCULAR PAINS
8.1.2 INCREASING UNHYGIENIC & SEDENTARY LIFESTYLE
8.1.3 RISE IN TRAUMATIC INJURIES
8.1.4 RISE IN THE GERIATRIC POPULATION
8.2 RESTRAINTS
8.2.1 HIGH COST & RISKS ASSOCIATED WITH EYE SURGERY & TREATMENT
8.2.2 LACK OF HEALTH INSURANCE AMONGST THE POPULATION, ESPECIALLY WITHIN THE DEVELOPING COUNTRIES
8.2.3 SIDE EFFECTS ASSOCIATED WITH TREATMENT DRUGS
8.3 OPPORTUNITIES
8.3.1 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
8.3.3 RISING AWARENESS TO PREVENT THE BURDEN OF EYE DISEASES
8.4 CHALLENGE
8.4.1 LACK OF SKILLED PROFESSIONALS
8.4.2 STRINGENT RULES & REGULATIONS FOR PRODUCT APPROVAL
9 EUROPE OPHTHALMOLOGY MARKET, BY PRODUCTS
9.1 OVERVIEW
9.2 DEVICE
9.2.1 SURGICAL DEVICE
9.2.1.1 CATARACT SURGICAL DEVICES
9.2.1.2 OPHTHALMIC VISCOELASTIC DEVICES
9.2.1.2.1 PHACOEMULSIFICATION DEVICES
9.2.1.2.2 CATARACT SURGICAL LASERS
9.2.1.2.3 IOL INJECTORS
9.2.1.3 VITREORETINAL SURGICAL DEVICES
9.2.1.3.1 VITREORETINAL PACKS
9.2.1.3.2 VITRECTOMY MACHINES
9.2.1.3.3 VITRECTOMY PROBES
9.2.1.3.4 PHOTOCOAGULATION LASERS
9.2.1.3.5 ILLUMINATION DEVICES
9.2.1.4 REFRACTIVE SURGICAL DEVICES
9.2.1.4.1 FEMTOSECOND LASERS
9.2.1.4.2 EXCIMER LASERS
9.2.1.4.3 OTHER REFRACTIVE SURGICAL LASERS
9.2.1.5 GLAUCOMA SURGICAL DEVICES
9.2.1.5.1 GLAUCOMA DRAINAGE DEVICES
9.2.1.5.2 GLAUCOMA LASER SYSTEMS
9.2.1.5.3 MICRO INVASIVE GLAUCOMA SURGERY DEVICES
9.2.2 DIAGNOSTIC DEVICE
9.2.2.1 AUTOREFRACTORS & KERATOMETERS
9.2.2.2 TONOMETER
9.2.2.3 PHOROPTERS
9.2.2.4 RETINOSCOPES
9.2.2.5 OPHTHALMOSCOPES
9.2.2.6 PERIMETERS/VISUAL FIELD ANALYZERS
9.2.2.7 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
9.2.2.7.1 A- SCAN IMAGING SYSTEM
9.2.2.7.2 B-SCAN IMAGING SYSTEM
9.2.2.7.3 PACHYMETERS
9.2.2.7.4 ULTRASOUND BIOMICROSCOPES
9.2.2.8 LENSMETERS
9.2.2.9 CORNEAL TOPOGRAPHY SYSTEMS
9.2.2.10 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
9.2.2.11 FUNDUS CAMERAS
9.2.2.12 OPTICAL BIOMETRY SYSTEMS
9.2.2.13 SPECULAR MICROSCOPES
9.2.2.14 WAVEFRONT ABERROMETERS
9.2.2.15 CHART PROJECTORS
9.2.2.16 SLIT LAMPS
9.2.3 OPHTHALMIC SURGICAL ACCESSORIES
9.2.3.1 SURGICAL INSTRUMENTS & KITS
9.2.3.2 OPHTHALMIC FORCEPS
9.2.3.3 OPHTHALMIC SPATULA
9.2.3.4 OPHTHALMIC TIPS AND HANDLES
9.2.3.5 OPHTHALMIC CANNULAS
9.2.3.6 OPHTHALMIC SCISSORS
9.2.3.7 OTHERS SURGICAL ACCESSORIES
9.2.4 OPHTHALMIC MICROSCOPES
9.3 DRUGS
9.3.1 ANTI-INFLAMMATION DRUGS
9.3.1.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.1.2 STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.2 ALLERGIC CONJUNCTIVITIS
9.3.3 DRY EYE DRUGS
9.3.4 RETINAL DISORDER DRUGS
9.3.5 ANTI-GLAUCOMA DRUGS
9.3.5.1 MIOTICS
9.3.5.1.1 PILOCARPINE
9.3.5.1.2 ESERINE
9.3.5.2 BETA ADRENERGIC ANTAGONISTS
9.3.5.2.1 TIMOLAL MALEATE
9.3.5.2.2 BETAXOLOL
9.3.5.3 PROSTAGLANDIN ANALOGS
9.3.5.3.1 LATANOPROST
9.3.5.3.2 BIMATOPROST
9.3.5.3.3 TRAVOPROST
9.3.5.3.4 TAFLUPROST
9.3.5.3.5 LATANOPROSTENE
9.3.5.4 ALPHA ADRENERGIC AGONISTS
9.3.5.4.1 EPINEPHRINE
9.3.5.4.2 DEPIVEPRINE
9.3.5.5 ANTI-VEGF DRUGS
9.3.5.5.1 RANIBIZUMAB
9.3.5.5.2 BEVACIZUMAB
9.3.6 OTHERS
9.4 OTHERS
9.4.1 VISION CARE PRODUCTS
9.4.1.1 SPECTACLES
9.4.1.2 CONTACT LENSES
9.4.1.2.1 SOFT CONTACT LENSES
9.4.1.2.2 HYBRID CONTACT LENSES
9.4.1.2.3 RIGID GAS PERMEABLE LENSES
9.4.2 OTHERS
10 EUROPE OPHTHALMOLOGY MARKET, BY DISEASES
10.1 OVERVIEW
10.2 INFLAMMATORY DISEASES
10.3 CATARACT
10.4 REFRACTIVE DISORDERS
10.5 GLAUCOMA
10.6 AGE-RELATED MACULAR DEGENERATION
10.7 OTHERS
11 EUROPE OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE
11.1 OVERVIEW
11.2 BRANDED
11.3 GENERIC
12 EUROPE OPHTHALMOLOGY MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 EUROPE OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 EYE DROPS
13.2.2 EYE SOLUTION
13.2.3 CREAM & OINTMENTS
13.2.4 GEL
13.2.5 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 LOCAL OCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 INTRAVITREAL
13.4.3 RETROBULBAR
13.4.4 INTRACAMERAL
13.5 INJECTABLE
13.5.1 INTRAMUSCULAR
13.5.2 INTRAVENOUS
13.5.3 OTHERS
13.6 OTHERS
14 EUROPE OPHTHALMOLOGY MARKET, BY END USER
14.1 OVERVIEW
14.2 CLINICS
14.3 HOSPITALS
14.4 HOMECARE SETTINGS
14.5 OTHERS
15 EUROPE OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 RETAIL SHOPS
15.2.2 HOSPITAL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
15.4 OTHERS
16 EUROPE OPHTHALMOLOGY MARKET, BY GEOGRAPHY
16.1 EUROPE
16.1.1 GERMANY
16.1.2 U.K.
16.1.3 FRANCE
16.1.4 HUNGARY
16.1.5 LITHUANIA
16.1.6 AUSTRIA
16.1.7 IRELAND
16.1.8 NORWAY
16.1.9 POLAND
16.1.10 ITALY
16.1.11 SPAIN
16.1.12 RUSSIA
16.1.13 TURKEY
16.1.14 NETHERLANDS
16.1.15 SWITZERLAND
16.1.16 REST OF EUROPE
17 EUROPE OPHTHALMOLOGY MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: EUROPE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 ALCON
19.1.1 COMPANY SNAPSHOT
19.1.2 RECENT FINANCIALS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 REGENERON PHARMACEUTICALS INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 RECENT FINANCIALS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 JOHNSON & JOHNSON SERVICES, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 RECENT FINANCIALS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 REICHERT, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENT
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ABBVIE INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 RECENT FINANCIALS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BAUSCH & LOMB INCORPORATED
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 CARL ZEISS MEDITEC AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 ESSILORLUXOTTICA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMEN
19.1 F. HOFFMANN- LA ROCHE LTD
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 GLAUKOS
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 HEIDELBERG ENGINEERING GMBH
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 HOYA CORPORATION
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 LUMENIS BE LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 METALL ZUG AG
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 NEOVISION
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 NIDEK CO., LTD.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 SANTEN PHARMACEUTICAL CO., LTD.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT FINANCIALS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 RECENT FINANCIALS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 STAAR SURGICAL
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 THE COOPER COMPANIES INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TOPCON CORPORATION
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 VISIONIX
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 ZIEMER OPHTHALMIC SYSTEMS AG
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 EUROPE OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2 EUROPE DEVICE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 4 EUROPE SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 5 EUROPE OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 6 EUROPE VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 7 EUROPE REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 8 EUROPE GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 9 EUROPE DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 10 EUROPE OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 11 EUROPE OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 12 EUROPE DRUGS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 14 EUROPE ANTI INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 15 EUROPE ANTI GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 16 EUROPE MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 17 EUROPE BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 18 EUROPE PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 19 EUROPE ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 20 EUROPE ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 21 EUROPE OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 23 EUROPE VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 24 EUROPE CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION))
TABLE 25 EUROPE OPHTHALMOLOGY MARKET, BY DISEASES 2021-2030 (USD MILLION)
TABLE 26 EUROPE INFLAMMATORY DISEASES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE CATARACT IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE REFRACTIVE DISORDERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE GLAUCOMA IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE AGE-RELATED MACULAR DEGENERATION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 33 EUROPE BRANDED IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE GENERIC IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE OPHTHALMOLOGY MARKET, BY DRUG TYPE 2021-2030 (USD MILLION)
TABLE 36 EUROPE OVER THE COUNTER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PRESCRIPTION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE TOPICAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE ORAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 45 EUROPE INJECTABLES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 EUROPE CLINICS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE HOSPITALS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE HOME HEALTHCARE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 EUROPE RETAIL SALES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL 2021-2030 (USD MILLION)
TABLE 56 EUROPE DIRECT TENDER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 EUROPE OPHTHALMOLOGY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 59 EUROPE OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 EUROPE DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 EUROPE SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 EUROPE OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 EUROPE VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 64 EUROPE REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 65 EUROPE GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 66 EUROPE DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 67 EUROPE OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 68 EUROPE OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 69 EUROPE DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 70 EUROPE ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 71 EUROPE ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 72 EUROPE MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 73 EUROPE BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 74 EUROPE PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 75 EUROPE ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 76 EUROPE ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 77 EUROPE OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 78 EUROPE VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 79 EUROPE CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 80 EUROPE OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 81 EUROPE OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 82 EUROPE OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 EUROPE OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 84 EUROPE TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 85 EUROPE ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 EUROPE LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 EUROPE INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 EUROPE OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 EUROPE OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 90 EUROPE RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 91 GERMANY OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 92 GERMANY DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 93 GERMANY SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 94 GERMANY OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 95 GERMANY VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 96 GERMANY REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 97 GERMANY GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 98 GERMANY DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 99 GERMANY OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 100 GERMANY OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 101 GERMANY DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 GERMANY ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 GERMANY ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 GERMANY MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 GERMANY BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 GERMANY PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 GERMANY ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 GERMANY ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 GERMANY OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 GERMANY VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 GERMANY CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 GERMANY OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 113 GERMANY OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 114 GERMANY OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 GERMANY TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 GERMANY ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 GERMANY LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 119 GERMANY INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 120 GERMANY OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 121 GERMANY OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 122 GERMANY RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 123 U.K. OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 124 U.K. DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 125 U.K. SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 126 U.K. OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 127 U.K. VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 128 U.K. REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 129 U.K. GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 130 U.K. DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 131 U.K. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 132 U.K. OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 133 U.K. DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 134 U.K. ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 135 U.K. ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 136 U.K. MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 137 U.K. BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 138 U.K. PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 139 U.K. ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 140 U.K. ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 141 U.K. OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 142 U.K. VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 143 U.K. CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 144 U.K. OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 145 U.K. OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 146 U.K. OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 147 U.K. OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 U.K. TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 149 U.K. ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 150 U.K. LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 151 U.K. INJECTABLE IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 152 U.K. OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 153 U.K. OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 154 U.K. RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 155 FRANCE OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 FRANCE DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 FRANCE SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 FRANCE OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 FRANCE VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 FRANCE REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 FRANCE GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 FRANCE DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 163 FRANCE OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 164 FRANCE OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 165 FRANCE DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 166 FRANCE ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 167 FRANCE ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 168 FRANCE MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 169 FRANCE BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 170 FRANCE PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 171 FRANCE ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 172 FRANCE ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 173 FRANCE OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 174 FRANCE VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 175 FRANCE CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 176 FRANCE OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 177 FRANCE OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 178 FRANCE OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 FRANCE OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 180 FRANCE TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 181 FRANCE ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 182 FRANCE LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 183 FRANCE INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 184 FRANCE OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 FRANCE OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 FRANCE RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 187 HUNGARY OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 188 HUNGARY DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 189 HUNGARY SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 190 HUNGARY OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 191 HUNGARY VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 192 HUNGARY REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 193 HUNGARY GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 194 HUNGARY DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 195 HUNGARY OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 196 HUNGARY OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 197 HUNGARY DRUG IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 198 HUNGARY ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 199 HUNGARY ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 200 HUNGARY MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 201 HUNGARY BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 202 HUNGARY PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 203 HUNGARY ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 204 HUNGARY ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 205 HUNGARY OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 206 HUNGARY VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 207 HUNGARY CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 208 HUNGARY OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 209 HUNGARY OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 210 HUNGARY OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 211 HUNGARY OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 212 HUNGARY TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 213 HUNGARY ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 214 HUNGARY LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 215 HUNGARY INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 216 HUNGARY OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 HUNGARY OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 218 HUNGARY RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 219 LITHUANIA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 220 LITHUANIA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 221 LITHUANIA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 222 LITHUANIA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 223 LITHUANIA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 224 LITHUANIA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 225 LITHUANIA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 226 LITHUANIA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 227 LITHUANIA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 228 LITHUANIA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 229 LITHUANIA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 230 LITHUANIA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 231 LITHUANIA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 232 LITHUANIA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 233 LITHUANIA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 234 LITHUANIA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 235 LITHUANIA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 236 LITHUANIA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 237 LITHUANIA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 238 LITHUANIA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 239 LITHUANIA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 240 LITHUANIA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 241 LITHUANIA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 242 LITHUANIA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 243 LITHUANIA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 244 LITHUANIA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 245 LITHUANIA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 246 LITHUANIA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 247 LITHUANIA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 248 LITHUANIA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 249 LITHUANIA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 250 LITHUANIA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 251 AUSTRIA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 252 AUSTRIA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 253 AUSTRIA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 254 AUSTRIA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 255 AUSTRIA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 256 AUSTRIA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 257 AUSTRIA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 258 AUSTRIA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 259 AUSTRIA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 260 AUSTRIA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 261 AUSTRIA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 262 AUSTRIA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 263 AUSTRIA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 264 AUSTRIA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 265 AUSTRIA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION))
TABLE 266 AUSTRIA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 267 AUSTRIA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 268 AUSTRIA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 269 AUSTRIA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 270 AUSTRIA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 271 AUSTRIA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 272 AUSTRIA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 273 AUSTRIA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 274 AUSTRIA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 275 AUSTRIA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 276 AUSTRIA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 277 AUSTRIA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 278 AUSTRIA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 279 AUSTRIA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 280 AUSTRIA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 281 AUSTRIA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 282 AUSTRIA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 283 IRELAND OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 284 IRELAND DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 285 IRELAND SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 286 IRELAND OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 287 IRELAND VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 288 IRELAND REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 289 IRELAND GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 290 IRELAND DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 291 IRELAND OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 292 IRELAND OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 293 IRELAND DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 294 IRELAND ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 295 IRELAND ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 296 IRELAND MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 297 IRELAND BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 298 IRELAND PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 299 IRELAND ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 300 IRELAND ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 301 IRELAND OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 302 IRELAND VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 303 IRELAND CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 304 IRELAND OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 305 IRELAND OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 306 IRELAND OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 307 IRELAND OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 308 IRELAND TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 309 IRELAND ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 310 IRELAND LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 311 IRELAND INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 312 IRELAND OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 313 IRELAND OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 314 IRELAND RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 315 NORWAY OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 316 NORWAY DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 317 NORWAY SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 318 NORWAY OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 319 NORWAY VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION))
TABLE 320 NORWAY REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 321 NORWAY GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 322 NORWAY DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 323 NORWAY OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 324 NORWAY OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 325 NORWAY DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 326 NORWAY ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 327 NORWAY ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 328 NORWAY MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 329 NORWAY BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 330 NORWAY PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 331 NORWAY ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 332 NORWAY ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 333 NORWAY OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 334 NORWAY VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 335 NORWAY CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 336 NORWAY OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 337 NORWAY OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 338 NORWAY OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 339 NORWAY OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 340 NORWAY TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 341 NORWAY ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 342 NORWAY LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 343 NORWAY INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 344 NORWAY OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 345 NORWAY OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 346 NORWAY RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 347 POLAND OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 348 POLAND DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 349 POLAND SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 350 POLAND OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 351 POLAND VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 352 POLAND REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 353 POLAND GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 354 POLAND DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 355 POLAND OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 356 POLAND OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 357 POLAND DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 358 POLAND ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 359 POLAND ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 360 POLAND MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 361 POLAND BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 362 POLAND PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 363 POLAND ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 364 POLAND ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 365 POLAND OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 366 POLAND VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 367 POLAND CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 368 POLAND OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 369 POLAND OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 370 POLAND OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 371 POLAND OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 372 POLAND TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 373 POLAND ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 374 POLAND LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 375 POLAND INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 376 POLAND OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 377 POLAND OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 378 POLAND RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 379 ITALY OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 380 ITALY DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 381 ITALY SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 382 ITALY OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 383 ITALY VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 384 ITALY REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 385 ITALY GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 386 ITALY DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 387 ITALY OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 388 ITALY OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 389 ITALY DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 390 ITALY ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 391 ITALY ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 392 ITALY MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 393 ITALY BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 394 ITALY PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 395 ITALY ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 396 ITALY ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 397 ITALY OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 398 ITALY VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 399 ITALY CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 400 ITALY OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 401 ITALY OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 402 ITALY OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 403 ITALY OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 404 ITALY TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 405 ITALY ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 406 ITALY LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 407 ITALY INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 408 ITALY OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 409 ITALY OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 410 ITALY RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 411 SPAIN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 412 SPAIN DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 413 SPAIN SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 414 SPAIN OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 415 SPAIN VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 416 SPAIN REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 417 SPAIN GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 418 SPAIN DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 419 SPAIN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 420 SPAIN OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 421 SPAIN DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 422 SPAIN ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 423 SPAIN ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 424 SPAIN MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 425 SPAIN BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 426 SPAIN PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 427 SPAIN ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 428 SPAIN ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 429 SPAIN OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 430 SPAIN VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 431 SPAIN CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 432 SPAIN OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 433 SPAIN OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 434 SPAIN OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 435 SPAIN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 436 SPAIN TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 437 SPAIN ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 438 SPAIN LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 439 SPAIN INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 440 SPAIN OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 441 SPAIN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 442 SPAIN RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 443 RUSSIA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 444 RUSSIA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 445 RUSSIA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 446 RUSSIA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 447 RUSSIA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 448 RUSSIA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 449 RUSSIA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 450 RUSSIA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 451 RUSSIA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 452 RUSSIA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 453 RUSSIA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 454 RUSSIA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 455 RUSSIA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 456 RUSSIA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 457 RUSSIA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 458 RUSSIA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 459 RUSSIA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 460 RUSSIA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 461 RUSSIA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 462 RUSSIA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 463 RUSSIA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 464 RUSSIA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 465 RUSSIA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 466 RUSSIA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 467 RUSSIA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 468 RUSSIA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 469 RUSSIA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 470 RUSSIA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 471 RUSSIA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 472 RUSSIA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 473 RUSSIA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 474 RUSSIA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 475 TURKEY OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 476 TURKEY DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 477 TURKEY SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 478 TURKEY OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 479 TURKEY VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 480 TURKEY REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 481 TURKEY GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 482 TURKEY DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 483 TURKEY OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 484 TURKEY OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 485 TURKEY DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 486 TURKEY ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 487 TURKEY ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 488 TURKEY MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 489 TURKEY BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 490 TURKEY PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 491 TURKEY ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 492 TURKEY ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 493 TURKEY OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 494 TURKEY VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 495 TURKEY CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 496 TURKEY OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 497 TURKEY OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 498 TURKEY OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 499 TURKEY OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 500 TURKEY TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 501 TURKEY ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 502 TURKEY LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 503 TURKEY INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 504 TURKEY OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 505 TURKEY OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 506 TURKEY RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 507 NETHERLANDS OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 508 NETHERLANDS DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 509 NETHERLANDS SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 510 NETHERLANDS OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 511 NETHERLANDS VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 512 NETHERLANDS REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 513 NETHERLANDS GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 514 NETHERLANDS DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 515 NETHERLANDS OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 516 NETHERLANDS OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 517 NETHERLANDS DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 518 NETHERLANDS ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 519 NETHERLANDS ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 520 NETHERLANDS MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 521 NETHERLANDS BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 522 NETHERLANDS PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION))
TABLE 523 NETHERLANDS ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 524 NETHERLANDS ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 525 NETHERLANDS OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 526 NETHERLANDS VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 527 NETHERLANDS CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 528 NETHERLANDS OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 529 NETHERLANDS OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 530 NETHERLANDS OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 531 NETHERLANDS OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 532 NETHERLANDS TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 533 NETHERLANDS ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 534 NETHERLANDS LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 535 NETHERLANDS INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 536 NETHERLANDS OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 537 NETHERLANDS OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 538 NETHERLANDS RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 539 SWITZERLAND OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 540 SWITZERLAND DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 541 SWITZERLAND SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 542 SWITZERLAND OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 543 SWITZERLAND VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 544 SWITZERLAND REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 545 SWITZERLAND GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 546 SWITZERLAND DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 547 SWITZERLAND OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 548 SWITZERLAND OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 549 SWITZERLAND DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 550 SWITZERLAND ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 551 SWITZERLAND ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 552 SWITZERLAND MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 553 SWITZERLAND BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 554 SWITZERLAND PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 555 SWITZERLAND ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 556 SWITZERLAND ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 557 SWITZERLAND OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 558 SWITZERLAND VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 559 SWITZERLAND CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 560 SWITZERLAND OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 561 SWITZERLAND OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 562 SWITZERLAND OPHTHALMOLOGY MARKET, BY DRUG TYPE 2021-2030 (USD MILLION)
TABLE 563 SWITZERLAND OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 564 SWITZERLAND TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 565 SWITZERLAND ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 566 SWITZERLAND LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 567 SWITZERLAND INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 568 SWITZERLAND OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 569 SWITZERLAND OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 570 SWITZERLAND RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 571 REST OF EUROPE OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 EUROPE OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 2 EUROPE OPHTHALMOLOGY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE OPHTHALMOLOGY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE OPHTHALMOLOGY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE OPHTHALMOLOGY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE OPHTHALMOLOGY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE OPHTHALMOLOGY MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE OPHTHALMOLOGY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE OPHTHALMOLOGY MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF OPHTHALMIC DISORDERS& INCREASING GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE EUROPE OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 12 THE DEVICE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE OPHTHALMOLOGY MARKET
FIGURE 14 EUROPE OPHTHALMOLOGY MARKET: BY PRODUCTS, 2022
FIGURE 15 EUROPE OPHTHALMOLOGY MARKET: BY PRODUCTS, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE OPHTHALMOLOGY MARKET: BY PRODUCTS, CAGR (2023-2030)
FIGURE 17 EUROPE OPHTHALMOLOGY MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 18 EUROPE OPHTHALMOLOGY MARKET: BY DISEASES, 2022
FIGURE 19 EUROPE OPHTHALMOLOGY MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE OPHTHALMOLOGY MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 21 EUROPE OPHTHALMOLOGY MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 22 EUROPE OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE ,2022
FIGURE 23 EUROPE OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, CAGR (2023-2030)
FIGURE 25 EUROPE OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE
FIGURE 26 EUROPE OPHTHALMOLOGY MARKET: BY DRUG TYPE ,2022
FIGURE 27 EUROPE OPHTHALMOLOGY MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE OPHTHALMOLOGY MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 29 EUROPE OPHTHALMOLOGY MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 EUROPE OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 31 EUROPE OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 33 EUROPE OPHTHALMOLOGY MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 EUROPE OPHTHALMOLOGY MARKET: BY END USER, 2022
FIGURE 35 EUROPE OPHTHALMOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE OPHTHALMOLOGY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 EUROPE OPHTHALMOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 EUROPE OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 40 EUROPE OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 41 EUROPE OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 EUROPE OPHTHALMOLOGY MARKET: SNAPSHOT (2022)
FIGURE 43 EUROPE OPHTHALMOLOGY MARKET: BY COUNTRY (2022)
FIGURE 44 EUROPE OPHTHALMOLOGY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 EUROPE OPHTHALMOLOGY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 EUROPE OPHTHALMOLOGY MARKET: PRODUCTS (2023-2030)
FIGURE 47 EUROPE OPHTHALMOLOGY MARKET: COMPANY SHARE 2022 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
